Impact of Long-Term Statin Therapy on Influenza Incidence and Overall Mortality: A Real-World Data Analysis

dc.contributor.authorToledo Zavaleta, Diana Isabel
dc.contributor.authorCartanyà Hueso, Àurea
dc.contributor.authorPagès Fernández, Constança
dc.contributor.authorMorros Pedrós, Rosa
dc.contributor.authorGiner Soriano, Maria
dc.contributor.authorDomínguez García, Àngela
dc.contributor.authorVilaplana Carnerero, Carles
dc.contributor.authorTor Roca, Alba
dc.contributor.authorGrau, Maria
dc.date.accessioned2026-10-22T15:39:05Z
dc.date.available2026-10-22T15:39:05Z
dc.date.issued2026-06-26
dc.date.updated2026-10-22T15:39:05Z
dc.description.abstractBackground/Objectives: The study’s goal is to assess the association between long-term statin therapy and influenza incidence, influenza severity, and all-cause mortality. Methods: Two population-based dynamic cohorts (exposed and unexposed to statins) were followed from 2010 to 2019. Participants were 60 years or older; frail patients were excluded. The primary outcomes were influenza incidence, influenza-related intensive care unit (ICU) admission as a proxy for severity, and all-cause mortality. The exposed cohort comprised new statin users with a minimum of two pharmacy invoices within 90 days of enrollment. Adjusted risk ratios (aRRs) for influenza incidence, ICU admission, and mortality rate were calculated using Poisson regression. Results: The initial study population of 639,564 individuals was evenly split into exposed (319,782) and unexposed (319,782) cohorts; mean age was 71 years (standard deviation: 8 years), and 57% were women. Compared to non-users, new statin users showed a higher influenza incidence [9.39 (95% confidence interval: 9.36–9.42) vs. 7.64 (7.61–7.66) per 1000 person-years], ICU admission [1.65 (1.65–1.66) vs. 1.36 (1.35–1.36) per 1000 person-years], and overall mortality rate [97.09 (96.75–97.43) vs. 94.15 (93.82–94.47) per 1000 person-years]. Adjusted analysis revealed no significant association between statin use and influenza incidence [aRR: 1.04 (0.98–1.10)] or influenza-related ICU admission [aRR: 1.03 (0.89–1.19)] and shifted the effect on mortality from harmful to beneficial [aRR: 0.88 (0.87–0.89)]. Conclusions: Despite new users’ greater vulnerability at the start of treatment, our findings indicate that statins do not influence influenza incidence or severity but reduce all-cause mortality, warranting further exploration of their anti-inflammatory properties.
dc.format.extent14 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec772802
dc.identifier.urihttps://hdl.handle.net/2445/232272
dc.language.isoeng
dc.publisherMDPI
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/pharma5020010
dc.relation.ispartofPharmacoepidemiology, 2026, vol. 5, num.2
dc.relation.urihttps://doi.org/10.3390/pharma5020010
dc.rightscc-by (c) Toledo, D. et al., 2026
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subject.classificationEstatines (Medicaments cardiovasculars)
dc.subject.classificationGrip
dc.subject.classificationMorbiditat
dc.subject.otherStatins (Cardiovascular agents)
dc.subject.otherInfluenza
dc.subject.otherMorbidity
dc.titleImpact of Long-Term Statin Therapy on Influenza Incidence and Overall Mortality: A Real-World Data Analysis
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
945584.pdf
Mida:
1.38 MB
Format:
Adobe Portable Document Format